Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study

Starting and maximum doses of colchicine were considered according to EULAR recommendations.4,5 A specific questionnaire on compliance (adapted from Ben-Chetrit and Aamar7) and some aspects of the quality of life (limitations in daily activity, chronic fatigue or pain, and loss of school/workdays) were also collected (see this article's Online Repository at www.jaci-inpractice.org), as recently indicated as basic information for the evaluation of the response to colchicine in FMF.5 In January 2020, complete baseline information was available for 341 Italian patients with FMF in the registry: 262 patients had at least 1 longitudinal follow-up visit and were eligible for the study; 221 (125 children, 91.2%; 96 adults, 96.9%) were treated exclusively with colchicine, with a median follow-up of 3.7 years (Table E1, available in this article's Online Repository at www.jaci-inpractice.org). [...]most of them displayed a clear reduction of fever episodes in respect to the pretreatment period, thus suggesting us to maintain the ongoing dosage. Four centers (Ospedale Gaslini, Ospedale Bambino Gesù, Policlinico San Matteo, and University of Brescia) of this publication are members of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (Project ID No 739543).Online Repository Response to colchicine 18 y mg/d∗ mg/kg/d∗ mg/d∗ mg/kg/d∗ mg/d∗ mg/kg/d∗ mg/d∗ mg/kg/d∗ Complete response 0.5 (0.5-0.5) 0.026 (0.024-0.028) 0.75 (0.5-1) 0.028 (0.016-0.053) 1.0 (0.5-1.5) 0.026 (0.010-0.044) 1 (0.5-2) 0.016 (0.006-0.033) Partial response (